The REAL Pfizer Papers : What Investigators Missed in the Documents Released by the FDA

How did they miss it? Thousands of volunteers participated in the DailyClout project to examine the 'Pfizer Papers', that trove of documents wrested from regulators after the FDA sought to delay disclosure for decades, but they overlooked some key findings...

• Pfizer acknowledged to the FDA that its ‘vaccine’ trials in adolescents were illegally premature.

• The papers included CVs (resumés) of the investigators conducting clinical trials for Pfizer’s COVID ‘vaccine’. The vast majority signed their CVs in the Spring and Summer of 2020, consistent with the timing of those trials, but 13 investigators had signed in 2018 and 2019. Was Pfizer lining them up before this novel disease had even appeared?

• Pfizer was in talks with the FDA about injecting newborns, not just the six-month-olds reached on June 17, 2022 after the FDA had issued a series of ‘emergency-use authorizations’ (EUA) to younger and younger age groups.

These observations, and many more, are presented in clear, accessible language, all properly sourced and referenced, that a layman—and even some of your 'normie' friends—can easily understand.

LeRoy also sets the Papers in the context of broader scientific analysis, shedding more light on the Big Pharma agenda. Even if you're "deep down the Rabbit Hole," you will find fresh insights here.

Essayez 15 heures gratuitement

  • Lis et écoute dès aujourd'hui
  • Sans engagement, annulez à tout moment
Essayer gratuitement

Transforme chaque instant en aventure

  • Emportez des centaines de milliers d'histoires directement dans votre poche
  • Sans engagement, annulez à tout moment
Essayer gratuitement
Femme souriante regardant par la fenêtre d'un train, portant des écouteurs et tenant son téléphone

Commencez ce livre dès aujourd’hui pour 0 €

  • Accédez à tous les livres de l'app pendant la période d'essai
  • Sans engagement, annulez à tout moment
Essayer gratuitement
Plus de 52 000 personnes ont noté Nextory 5 étoiles sur l'App Store et Google Play.